Weekly Canna Boss Babe Update: DEA Cannabis Rescheduling Briefs
This week’s U.S. cannabis policy update covers developments from October 20–26, 2026. Federal rescheduling remains unresolved, Missouri issued consequential hemp and consumer-data guidance, Massachusetts released draft testing rules, Oklahoma recalled two medical-marijuana flower batches, and Israel advanced a trade investigation involving Canadian medical cannabis.
Follow the U.S. Cannabis Policy & News Tracker for ongoing federal, state, local, and global cannabis policy updates.
Federal Updates: DEA Cannabis Rescheduling
DEA judge sets limited briefing schedule
Legal status: Procedural order — not a final rescheduling decision. On October 22, DEA Chief Administrative Law Judge Derek C. Julius denied opponents’ request to reopen the broader marijuana rescheduling hearing for more testimony and discovery. He admitted a Government Accountability Office report into the record and invited limited briefing on its relevance.
Deadlines: Initial briefs are due October 29, 2026, and replies are due November 5, 2026. The proceeding remains stayed through the briefing period, with the stay set to expire when that schedule closes.
What it means: The order moves the proceeding forward procedurally, but it does not broadly reschedule or legalize adult-use marijuana. The separate federal treatment already established for qualifying state-licensed medical cannabis and certain FDA-approved products is outside this narrow briefing dispute.
State Regulations
Missouri: HB 2641 guidance changes hemp and data rules
Legal status: Enacted law and agency guidance, updated October 23. Missouri’s Division of Cannabis Regulation says HB 2641 restricts dispensaries from creating or retaining consumer-identifying information without affirmative agreement. Violations may carry a $500 penalty per occurrence.
The guidance also treats many intoxicating hemp-derived cannabinoid products as marijuana under Article XIV. Unlicensed sale or distribution can trigger fines or criminal prosecution. For licensed cannabis businesses, externally sourced hemp products must contain no more than 0.3% total THC and no more than 0.4 milligrams of total THC; synthetic or chemically converted cannabinoids are prohibited.
Transition date: Certain beverages made with naturally occurring, non-synthesized cannabinoids remain temporarily outside Article XIV until December 11, 2026, subject to a 21-and-older sales restriction. Operators should also review data collected through loyalty, delivery, and intake systems for affirmative-consent compliance.
Primary source: Missouri DHSS — HB 2641 Guidance
Massachusetts: Draft cannabis testing rules released
Legal status: Draft proposal — not an effective regulation. On October 22, the Cannabis Control Commission began reviewing proposed rules for independent testing laboratories and cannabis-product testing. The draft addresses laboratory quality systems, sampling and retention, contaminant limits, retesting, remediation, and repurposing products after failed tests.
Next steps: Commissioners are scheduled to discuss the draft on November 12, 2026. A formal public-comment period is expected in early 2027. Licensees and laboratories should treat the text as a preview and prepare evidence-based comments rather than changing compliance systems as though the draft were final.
Primary source: Massachusetts CCC — Draft Testing Regulations
U.S. Cannabis Industry News
Oklahoma recalls two medical-marijuana flower batches
Status: Agency product recall issued October 20. The Oklahoma Medical Marijuana Authority recalled two flower production batches from Blue Collar Criminals Collective after the grower and a dispensary reported that the batches failed required testing after transfer to dispensaries.
What it means: Oklahoma patients, dispensaries, and other licensees should check the state’s recalled-product list and follow OMMA instructions for affected inventory. This is a batch-specific safety action, not a statewide ban on flower.
Primary source: OMMA — October 20 Product Recall
Global Cannabis & Industry Watch
Israel names Canadian exporters in anti-dumping inquiry
Legal status: Trade investigation — no final duties announced. On October 22, Israel’s Commissioner for Trade Levies identified GrowCo, Cielo Verde Quebec Inc., 2323414 Alberta Ltd., and Koots Canna Ltd. for examination in the reopened anti-dumping investigation into Canadian medical-cannabis imports.
Deadline and impact: Named parties were given five business days from the announcement to comment on or object to the selection. The inquiry could affect market access and pricing, but the selection of exporters is a procedural step and should not be reported as a tariff decision.
Advocacy Points
• DEA’s October 22 order sets briefing deadlines; it does not complete broad cannabis rescheduling or legalize adult-use marijuana.
• Missouri businesses should separate marijuana rules from hemp rules and audit loyalty, delivery, and intake data for affirmative consumer consent.
• Massachusetts testing rules are still a draft. Public comment is the point where operators, patients, scientists, and laboratories can submit evidence before final adoption.
• Product recalls should be shared with batch-level precision. Avoid language that implies a broader product category is unsafe or prohibited.
• An anti-dumping investigation is not the same as an imposed tariff. Accurate advocacy distinguishes an inquiry, a preliminary finding, and a final trade measure.
Read the October 19, 2026 Weekly Canna Boss Babe Update for the immediately previous edition.
This article is for educational and advocacy purposes only and is not legal advice. Cannabis and hemp laws change quickly. Verify current requirements with the appropriate government agency or qualified legal counsel before making compliance or business decisions.
Comments